Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637662 | 1.00 | AKR1C1 (0.47) | AKR1C1OPRM1OPRL1LMNAHTT | |
| SCHEMBL487380 | 1.00 | AKR1C1 (0.47) | AKR1C1OPRM1OPRL1LMNAHTT | |
| Ammonia Solution, Strong SCHEMBL6650400 | 0.98 | AKR1C1 (0.45) | AKR1C1OPRM1OPRL1LMNAHTT | |
| SCHEMBL5665997 | 0.86 | AKR1C1 (0.40) | AKR1C1OPRM1OPRL1LMNAHTT | |
| Potassium Ion SCHEMBL11295824 | 0.85 | AKR1C1 (0.38) | AKR1C1OPRM1OPRL1LMNAHTT | |
| SCHEMBL6435655 | 0.85 | AKR1C1 (0.39) | AKR1C1OPRM1OPRL1LMNAHTT | |
| SCHEMBL5180168 | 0.83 | LDHA (0.43) | AKR1C1OPRM1OPRL1LMNAHTT | |
| SCHEMBL9852819 | 0.81 | L3MBTL1 (0.42) | LMNAALDH1A1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL7806202 | 0.81 | HSD11B1 (0.46) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL8765171 | 0.81 | LMNA (0.41) | AKR1C1OPRM1OPRL1LMNAHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601778-B1 | STEREOSELECTIVE CHEMOENZYMATIC PROCESS FOR PREPARING OPTICALLY ENRICHED PHENYLGLYCIDATES | COUNCIL SCIENT IND RES (IN) | 2008-07-02 | — | — | EP | claimed |
| EP-1601778-B1 | STEREOSELECTIVE CHEMOENZYMATIC PROCESS FOR PREPARING OPTICALLY ENRICHED PHENYLGLYCIDATES | COUNCIL SCIENT IND RES (IN) | 2008-07-02 | — | — | EP | disclosed |
| EP-1601778-A1 | STEREOSELECTIVE CHEMOENZYMATIC PROCESS FOR PREPARING OPTICALLY ENRICHED PHENYLGLYCIDATES | Council of Scientific and Industrial Research (IN) | 2005-12-07 | — | — | EP | disclosed |
| US-20040259943-A1 | Stereoselective chemoenzymatic process for the preparation of optically enriched phenylglycidates as precursors of taxol side chain | COUNCIL OF SCIENTIFIC AND INDUSTRIAL (IN) | 2004-12-23 | — | — | US | disclosed |
| WO-2004081219-A1 | STEREOSELECTIVE CHEMOENZYMATIC PROCESS FOR PREPARING OPTICALLY ENRICHED PHENYLGLYCIDATES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-09-23 | — | — | WO | disclosed |
| US-20030013889-A1 | Process for the preparation of taxane derivatives | AVENTIS PHARMA S.A. | 2003-01-16 | — | — | US | disclosed |
| US-6433180-B1 | CHEMICAL INTERMEDIATE FOR TAXOL | AVENTIS PHARMA S.A. (FR) | 2002-08-13 | — | — | US | disclosed |
| US-5686623-A | Method for preparing taxane derivatives | RHONE-POULENC RORER, S.A. (FR) | 1997-11-11 | — | — | US | disclosed |
| EP-0157327-A2 | Novel compounds for detecting the presence of hydrolytic analytes in a test sample | MILES INC. (US) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013889-A1 | Process for the preparation of taxane derivatives | AR, CBR1, CBR3 | AKR1C1 14/4885OPRM1 234/4885OPRL1 299/4885 |
| US-20040259943-A1 | Stereoselective chemoenzymatic process for the preparation of optically enriched phenylglycidates as precursors of taxol side chain | GMDS, GPI, B3GAT3 | AKR1C1 82/4885OPRM1 1934/4885OPRL1 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.